OSI Confident On Tarceva After Iressa Approval; Brain Cancer Is Back-Up Plan
Executive Summary
OSI Pharmaceuticals is confident about Tarceva's prospects for FDA clearance based on the recent Subpart H approval of AstraZeneca's Iressa
You may also be interested in...
Roche Will Challenge Amgen In U.S. EPO Market; Oncology Business Growing
Roche expects to enter the U.S. EPO market with the continuous erythropoetin receptor activator R-744, Global Pharmaceuticals Head William Burns told securities analysts during a July 23 meeting in Zurich
Roche Will Challenge Amgen In U.S. EPO Market; Oncology Business Growing
Roche expects to enter the U.S. EPO market with the continuous erythropoetin receptor activator R-744, Global Pharmaceuticals Head William Burns told securities analysts during a July 23 meeting in Zurich
OSI Developing Tarceva I.V. Formulation, Expected To Aid In Reimbursement
OSI Pharmaceuticals is developing an intravenous formulation of its investigational anticancer agent Tarceva, which should facilitate reimbursement for the investigational anticancer agent